Apr 13, 2023 / Presentations

Assessing postsale rebates for prescription drugs in Medicare Part D

Research Areas:

Beneficiaries and Coverage, Drugs, Devices, and Tests, Medicare Spending and Financing

Mar 15, 2023 / Reports

March 2023 Report to the Congress: Medicare Payment Policy

Research Areas:

Ambulatory Care Settings, Beneficiaries and Coverage, Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality, Regional Issues

Mar 15, 2023 / Chapters

Appendix A: Commissioners’ voting on recommendations (March 2023 Report)

Research Areas:

Ambulatory Care Settings, Beneficiaries and Coverage, Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality, Regional Issues

Mar 15, 2023 / Chapters

Chapter 12: The Medicare prescription drug program (Part D): Status report (March 2023 Report)

Research Areas:

Drugs, Devices, and Tests, Quality

Mar 15, 2023 / Chapters

Executive Summary (March 2023 Report)

Research Areas:

Ambulatory Care Settings, Beneficiaries and Coverage, Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality, Regional Issues

Mar 15, 2023 / Press Releases

MedPAC releases March 2023 Report to the Congress: Medicare Payment Policy

Research Areas:

Ambulatory Care Settings, Beneficiaries and Coverage, Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality, Regional Issues

Mar 01, 2023 / Comment Letters

MedPAC comment on CMS’s advance notice of methodological changes for CY 2024 for Medicare Advantage capitation rates and Part C and D payment policies

Research Areas:

Private Plans, Quality

Feb 10, 2023 / Comment Letters

MedPAC comment on CMS’s proposed rule on policy and technical changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program for 2024

Research Areas:

Drugs, Devices, and Tests, Medicare Spending and Financing, Private Plans

Jan 13, 2023 / Presentations

Medicare Part D: Status report

Research Areas:

Drugs, Devices, and Tests, Medicare Spending and Financing, Quality

Sep 29, 2022 / Transcripts

September 29-30, 2022 meeting transcripts

Research Areas:

Beneficiaries and Coverage, Drugs, Devices, and Tests, Hospitals, Physicians And Other Health Professionals, Post-Acute Care, Quality